SEC Filings

S-1/A
AVEXIS, INC. filed this Form S-1/A on 02/01/2016
Entire Document
 

Table of Contents


MANAGEMENT

Executive Officers and Directors

          The following table provides information regarding our current executive officers and directors:

NAME
 
AGE
 
POSITION(S)

Executive Officers

         

Sean P. Nolan

    47   President, Chief Executive Officer and Director

Brian K. Kaspar, Ph.D. 

    42   Chief Scientific Officer and Director

Thomas J. Dee

    52   Senior Vice President and Chief Financial Officer

Sukumar Nagendran

    49   Senior Vice President and Chief Medical Officer

James J. L'Italien

    63   Senior Vice President, Chief Regulatory and Quality Officer

Andrew F. Knudten

    48   Senior Vice President, Manufacturing and Supply Chain

Non-Employee Directors

   
 
 

 

Daniel Welch

    58   Chairman of the Board of Directors

Terrence C. Kearney(1)(2)

    61   Director

Paul B. Manning(2)

    60   Director

Jonathan Leff(3)

    47   Director

Carole Nuechterlein(1)(3)

    54   Director

Bong Y. Koh(3)

    43   Director

Frank Verwiel(1)(2)

    53   Director

(1)
Member of the compensation committee.

(2)
Member of the audit committee.

(3)
Member of the nominating and corporate governance committee.

Executive Officers

          Sean P. Nolan has served as our President and Chief Executive Officer and as a member of our board of directors since June 2015. Prior to joining us, from February 2013 to April 2015, he was the chief business officer of InterMune, Inc., a biotechnology company later acquired by Roche Holding Ltd. While at InterMune, Mr. Nolan led multiple functions across the organization, including North American commercial operations, global marketing, corporate and business development and global manufacturing and supply chain. Mr. Nolan was also responsible for planning and executing the U.S. launch of InterMune's treatment for idiopathic pulmonary fibrosis, a rare and fatal lung disease with no other approved treatments. Mr. Nolan served as chief commercial officer at Reata Pharmaceuticals, Inc. from August 2011 to December 2012, where he led the market strategy development and commercialization of Reata Pharmaceuticals' first in-class product pipeline. From September 2004 to November 2010, Mr. Nolan worked at Ovation Pharmaceuticals, Inc., a company focused on orphan neurology diseases. He held numerous management positions during that period including president of Lundbeck Inc, the U.S. affiliate. Ovation Pharmaceuticals was acquired by H. Lundbeck A/S in March 2009 for $900 million. Mr. Nolan holds a B.A. in biology from John Carroll University. Mr. Nolan currently serves on the board of directors of Aquinox Pharmaceuticals, Inc. Our board of directors believes that Mr. Nolan is qualified to serve as a director based upon his role as our principal executive officer and his 24 years of broad leadership and management experience in the biopharmaceutical industry.

          Dr. Brian K. Kaspar has served as our Chief Scientific Officer since June 2015, a position he held from June 2015 to December 2015 in connection with his scientific advisory consulting services, and thereafter as our employee. Dr. Kaspar provided scientific advisory consulting services

137



© AveXis, Inc. All Rights Reserved.